Vision 2036
A decade of transformational growth
The group’s next ten years are written down, dated, and public. From a land acquisition at Dholera in 2026 to a group turnover of INR 3,000 crore in December 2036 — this is the roadmap, milestone by milestone.
The roadmap
Three acts, nine milestones
Nine milestones in three acts, carried between the group and Infocus Remedies, its manufacturing arm in Ahmedabad. Six are the commitments the group leads with; the rest are the steps that get there.
The group is here
August 2026
2026 — 2028
Build the capacity
Land, plant and the approvals that let either of them make a saleable tablet.
Oct 2026
Facility
Saifen
20,000 sq yd land acquisition at Dholera SIR — the site of India’s biggest biotech plant
Oct 2027
Facility
Infocus Remedies
Headline commitment
Green-field project at Sanand — a USFDA-approved hormonal manufacturing unit for tablets, capsules and injectables
2028
Regulatory
Infocus Remedies
Headline commitment
The Naroda OSD facility upgraded to EU-GMP
2030 — 2032
Turn it into revenue
The Vietnam factory comes on line, Infocus reaches scale, and the listing funds what follows.
2030
Facility
Saifen
Headline commitment
Vietnam’s largest pharmaceutical finished-product factory
The planned finished-product facility, Vietnam Dec 2031
Financial
Infocus Remedies
Turnover of INR 150 crore from Infocus Remedies Pvt. Ltd.
2032
Financial
Infocus Remedies
Headline commitment
Infocus Remedies IPO
Oct 2032
Facility
Saifen
Commencement of the biotech project at Dholera SIR
2034 — 2036
Arrive
A foothold in the largest pharmaceutical market on earth, the biotech plant running — and then the number the whole decade was for.
2034
Market entry
Saifen
Headline commitment
Saifen in the USA — a foothold in the US market
2035
Facility
Saifen
Headline commitment
India’s biggest biotech factory operational at Dholera
Where the decade lands
December 2036
INR 3,000 Cr
Saifen Group turnover
Every milestone above feeds this number — the factories build the capacity, the registrations open the markets, and the listing funds the rest.
Build part of this with us
Manufacturers, partners and future colleagues — the decade has room for all three.